Background {#Sec1}
==========

Previous epidemiological studies have shown an association between low folate intake and an increased urinary cancer risk \[[@CR1], [@CR2]\], meanwhile, folate deficiency may increase cancer risk through impaired DNA repair synthesis and disruption of DNA methylation, which may participate in cancer development \[[@CR3], [@CR4]\]. Methylenetetrahydrofolate reductase (MTHFR) plays a crucial role in the metabolism of folates and converts irreversibly 5,10-methylenetetrahydrofolate (5,10-MTHF) to 5-MTHF, which is the predominant circulatory form of folate and donates a metyl group for the re-methylation of homocysteine to methionine. Then, the methionine is metabolized to yield S-adenosylmethionine (SAM), which is the main methyl donor for vital methylation reactions and is required for DNA repair \[[@CR5], [@CR6]\]. In summary, this gene could influence cancer development.

A common single nucleotide polymorphism (SNP), A1298C/rs1801131 A/C, is located in the coding carboxy-terminal regulatory region domain \[[@CR7]\] and lymphocytes from individuals containing 1298CC genotype have been found to have approximately 60% of wild-type in vitro MTHFR activity \[[@CR8]\], which acts as a risk factor in cancer development.

Previous studies have investigated that MTHFR rs1801131 A/C was involved in the development of urinary cancers. However, the results of these studies remain conflicting. With the aim to measure the correlation, we performed this comprehensive meta-analysis by adopting all eligible studies \[[@CR9]--[@CR34]\].

Methods {#Sec2}
=======

The search strategy {#Sec3}
-------------------

We searched the Pubmed database (updated on Sep 10, 2018), using combinations of the keywords: 'polymorphism,' or 'variant' or 'mutation' and 'bladder cancer' or 'prostate cancer' or 'renal' and 'MTHFR' or 'methylenetetrahydrofolate reductase'. All the included studies met the following criteria (1) the association between MTHFR rs1801131 A/C and urinary cancer risk was evaluated; (2) case-control studies were designed; (3) available genotype frequency was collected. The major exclusion criteria were (1) duplications; (2) insufficient reporting data; (3) abstract, commentary, review, editorial article and conference article.

Data extraction {#Sec4}
---------------

Two authors carefully extracted data from all eligible publications, independently. The following data were collected from each study: first author's last name, year of publication, race of origin, cancer type, sample size (cases/controls), study design (hospital-based, HB, or population-based, PB), source of control for prostate cancer subgroup, Hardy-Weinberg equilibrium (HWE) of controls and genotype method.

Quality score assessment {#Sec5}
------------------------

The Newcastle-Ottawa Score (NOS) were selected to assess the quality of each study and to assess the various aspects of the methodology used by the observational research, which are relevant to the quality of the study, including the selection of cases, the comparability of groups and the determination of exposure. The total score is from 0 to 9 star. Studies with scores more than 7 are to be as high quality \[[@CR35]\].

Statistical analysis {#Sec6}
--------------------

Odd ratio (OR) with 95% confidence interval (CI) was used to measure the strength of the association between rs1801131 A/C and urinary cancers. Four different genetic models were applied to evaluate above association: allelic contrast (C-allele vs. A-allele), heterozygote comparison (CA vs. AA), dominant genetic model (CC + CA vs. AA), and recessive genetic model (CC vs. CA + AA). The ethnic descents were categorized as Caucasian, Asian, African, or Mixed. The control group based on sources was divided as follows: HB, PB, benign prostatic hyperplasia (BPH), and healthy man.

The statistical significance of the summary OR was determined with the *Z*-test. The heterogeneity was evaluated by both Cochrane *Q*-test \[[@CR36], [@CR37]\] and *I*^2^ metric \[[@CR38], [@CR39]\] ranging from 0 to 100%. When *P* for the heterogeneity test (*P*~*h*~) \< 0.10 and *I*^2^ \> 50% \[[@CR40]\], the pooled OR of each study was calculated by using the random-effects model; otherwise, the fixed-effects model was used \[[@CR41], [@CR42]\].

Subgroup analysis was performed according to the ethnicity and the source of cases to explore potential heterogeneity. The meta-regression analysis is a technique used to assess heterogeneity between the studies \[[@CR43]\]. This statistical approach determines whether there is a significant association between the study period and number of individuals with the pooled OR \[[@CR43]\]. The funnel plot asymmetry and publication bias were assessed using Egger's test and Begg's test, respectively \[[@CR44], [@CR45]\]. The departure of frequencies of MTHFR rs1801131 A/C from expected values under HWE was assessed in controls by using the Pearson chi-square test. All statistical tests were performed using the Stata software (Version 11.0; StataCorp LP, College Station, TX).

The PolyPhen-2 bioinformatic tool was used to predict the effects of gene SNPs on the translated proteins. In the PolyPhen-2 analysis, the scores could range from 0 to 1, where a score of zero meant 'benign' and a score of one meant 'probably damaging'.

Network of gene-interaction of MTHFR gene {#Sec7}
-----------------------------------------

The network of gene-gene interaction for MTHFR gene was utilized through String online server (<http://string-db.org/>) \[[@CR46]\].

Results {#Sec8}
=======

Study characteristics {#Sec9}
---------------------

After reviewing the title, abstract, and full text, 51 different papers were included for the final analysis, expect for papers focusing on meta-analyses, reviews, case-only studies, and other gene polymorphisms. For bladder cancer, Ouerhani et al. published two papers in 2007 and 2009 that contained duplicated data about, so we included the larger numbers from Ouerhani (2007) et al. \[[@CR24]\] in our analysis. Then, 15 different articles were review or meta-analysis. Moreover, another 9 papers were focus just only MTHFR C677T (rs1801133) polymorphism. Finally, we identified 26 different papers describing 28 case-control studies (11 case-control studies for prostate cancer, 14 for bladder cancer, and three for renal cell carcinoma, Table [1](#Tab1){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}) \[[@CR9]--[@CR34]\] to evaluate the association of MTHFR rs1801131 A/C. Study characteristics are shown in Table [1](#Tab1){ref-type="table"}. The distribution of genotypes in the controls was consistent with HWE in all studies, except for three papers. The average NOS of including studies is 7.571, which means our results is credible and representational. None of the control populations had a history of malignant diseases. Genotyping methods were conducted using polymerase chain reaction and restrictive fragment length polymorphism (PCR-RFLP), and TaqMan technologies. Finally, we checked the Minor Allele Frequency (MAF) reported for the five main worldwide populations in the 1000 Genomes Browser (<https://www.ncbi.nlm.nih.gov/snp/rs1801131#frequency_tab>): East Asian (EAS), 0.219; European (EUR), 0.313; African (AFR), 0.151; American (AMR), 0.15; and South Asian (SAS), 0.42 (Fig. [2](#Fig2){ref-type="fig"}). The MAF in our analysis was 0.331 and 0.325 in the case and control group, respectively, both higher than the results in the EAS from1000 Genomes Browser database. Table 1Study characteristics of all included studies about urinary cancerFirst authorYearOriginEthnicityDesignSource of controlCaseControlCaseControlHWE in controlGenotype methodNOSCCCAAACCCAAABladder cancer Ouerhani2007TunisiaAfricanHB11113164758937850.55PCR-RFLP6 Rouissi2009TunisiaAfricanHB18519110789710601210.478PCR-RFLP7 Cai2009ChinaAsianHB3123256912157922260.504PCR-RFLP7 Izmirli2011TurkeyCaucasianHB475032519729140.195PCR-RFLP6 Safarinejad2011IranCaucasianHB158316258548231151780.46PCR-RFLP8 Lin2004USAAfricanPB2121071408130.281PCR-RFLP9 Wang2009ChinaAsianPB2392503671694751710.719PCR-RFLP9 Beebe-Dimmer2012USACaucasianPB2182721410995341111270.211Taqman8 Karagas2005USACaucasianPB35054231146173552202670.333PCR-RFLP9 Lin2004USACaucasianPB41040930188192361841890.35PCR-RFLP9 Moore2007SpainCaucasianPB1068107874457537924295570.467TaqMan7 Sanyal2004GermanyCaucasianPB31124533133145241111100.6PCR-RFLP7 Lin2004USAMixedPB1717041315110.678PCR-RFLP9 Moore2004USAMixedPB10610894552845550.771TaqMan8Prostate cancer Cicek2004USAMixedPBHealthy43947839205195442012330.945PCR-RFLP8 Collin2009UKCaucasianPBHealthy15923035144673775289133914070.249PCR-RFLP9 Cai2010ChinaAsianHBBPH2172204631505711440.27PCR-RFLP6 Safarinejad2010IranCaucasianHBHealthy174348147090401501580.628PCR-RFLP7 Singal2004USACaucasianHBBPH814294329717180.396PCR-RFLP8 Wu2010TaiwanAsianHBHealthy2184361070138141352870.697PCR-RFLP7 Marchal2008SpainCaucasianHBHealthy17720917629822791080.193TaqMan7 Stevens2008USACaucasianPBHealthy110411091055184811254934910.94TaqMan7 Guelpen2006SwedenCaucasianPBHealthy2224342710887552031760.765TaqMan7 Muslumanoglu2009TurkeyCaucasianHBBPH91166441631444577\< 0.05PCR-RFLP6 López-Cortés2013USACaucasianPBHealthy1041102210011108\< 0.05PCR-RFLP9Renal cell carcinoma Ajaz2012PakistanAsianHB1681721910643810559\< 0.05PCR-RFLP6 Safarinejad2012IranCaucasianPB152304288836351311380.645PCR-RFLP9 Moore2008FranceCaucasianHB8181087853573761134834910.718PCR-RFLP7*HB* hospital-based, *PB* population-based, *PCR-RFLP* polymerase chain reaction and restrictive fragment length polymorphism, *HWE* Hardy--Weinberg equilibrium, *NOS* Newcastle-Ottawa ScoreFig. 1A flowchart illustrating the search strategy used to identify association studies for MTHFR rs1801131 polymorphism and urinary cancers' riskFig. 2C-allele frequencies for the MTHFR gene rs1801131 polymorphism among cases/controls stratified by ethnicity. Vertical line, T-allele frequency; Horizontal line, ethnicity type. EAS: East Asian; EUR: European; AFR: African; AMR: American; SAS: South Asian

Quantitative synthesis {#Sec10}
----------------------

### Total urinary cancers {#Sec11}

In the total analysis, significant increased relationship was found in both heterozygote comparison (OR = 1.12; 95% CI = 1.01--1.24; *P* = 0.387 for heterogeneity, Fig. [3](#Fig3){ref-type="fig"}) and dominant genetic model (OR = 1.09; 95% CI = 1.00--1.19; *P* = 0.003 for heterogeneity, Fig. [4](#Fig4){ref-type="fig"}) between MTHFR rs1801131 A/C and urinary cancer risk. At the same time, if we excluded three papers that were not consistent with HWE, also similar association was detected (Table [2](#Tab2){ref-type="table"}). Fig. 3Forest plot of whole urinary cancers' risk associated with the MTHFR rs1801131 polymorphism (CA vs. AA). The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CIFig. 4Forest plot of whole urinary cancers' risk associated with the MTHFR rs1801131 polymorphism (CC + CA vs. AA). The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CITable 2Total and stratified analysis of MTHFR rs1801131 A/C polymorphism and each urinary cancer variablesVariablesNCase/ControlC-allele vs. A-alleleCA vs. AACC vs. CA + AACC + CA vs. AAOR(95%CI) ***P***~**h**~OR(95%CI) ***P***~**h**~OR(95%CI) ***P***~**h**~OR(95%CI) ***P***~**h**~**Total**289110/121051.06(0.98--1.15)0.000**1.12(1.01--1.24)0.000**1.01(0.87--1.17)0.021**1.09(1.00--1.19)0.003H**WE258747/116571.03(0.96--1.11)0.001**1.11(1.00--1.24)0.000**0.93(0.84--1.02)0.4321.06(0.98--1.16)0.006**Prostate cancer** Total114419/65871.02(0.91--1.14)0.0160.99(0.91--1.07)0.5691.00(0.81--1.25)0.0620.99(0.91--1.07)0.253 HWE94224/63110.96(0.91--1.02)0.6560.99(0.91--1.07)0.4230.90(0.79--1.04)0.9180.97(0.90--1.05)0.461Ethnicity Caucasian83545/54531.02(0.88--1.17)0.0080.96(0.88--1.06)0.6220.96(0.83--1.10)0.0200.96(0.88--1.05)0.244 Asian2435/6561.02(0.81--1.27)0.2500.97(0.75--1.27)0.3921.23(0.61--2.48)0.5460.99(0.77--1.29)0.300 Mixed1439/478NANANANASource of control HB6958/14211.05(0.81--1.37)0.0030.93(0.78--1.12)0.7010.57(0.44--0.75)0.5301.09(0.64--1.85)0.017 PB53461/51660.97(0.91--1.04)0.4851.00(0.91--1.10)0.2691.08(0.85--1.36)0.0040.91(0.79--1.06)0.885 BPH3389/4281.22(0.70--2.13)0.0040.95(0.68--1.31)0.4111.22(0.44--3.40)0.3101.12(0.84--1.50)0.116 Healthy84030/61590.97(0.91--1.03)0.4540.99(0.91--1.08)0.4540.91(0.79--1.05)0.8630.98(0.90--1.06)0.39**Bladder cancer** Total143553/39551.04(0.93--1.16)0.0091.17(0.99--1.38)0.0050.89(0.74--1.06)0.2681.07(0.98--1.17)0.259Ethnicity Caucasian72512/29121.01(0.90--1.14)0.0851.17(0.92--1.48)0.0010.90(0.66--1.23)0.0331.09(0.93--1.29)0.069 Asian2551/575**1.35(1.15--1.60)0.941**0.98(0.76--1.27)0.5990.92(0.38--2.25)0.8931.11(0.91--1.36)0.792 Mixed2123/1250.75(0.51--1.09)0.2861.00(0.59--1.70)0.5941.04(0.41--2.65)0.4690.78(0.48--1.27)0.258 African3317/3430.91(0.72--1.14)0.627**1.63(1.17--2.25)0.498**0.88(0.44--1.75)0.7021.20(0.90--1.59)0.787Source of control HB5813/10131.16(0.90--1.49)0.0241.49(0.96--2.30)0.0021.24(0.84--1.84)0.137**1.29(1.09--1.54)0.235** PB92740/29420.99(0.91--1.07)0.1031.05(0.94--1.17)0.902**0.82(0.67--0.99)0.788**1.00(0.91--1.11)0.829**Renal cell carcinoma** Total31138/15631.33(0.90--1.98)0.0001.47(0.81--2.68)0.0001.50(0.86--2.59)0.0411.54(0.82--2.92)0.000 HWE2970/13911.32(0.72--2.42)0.0001.54(0.59--4.03)0.0001.26(0.74--2.14)0.0801.58(0.58--4.28)0.000*Ph* value of Q-test for heterogeneity test, *NA* not available

### Prostate cancer {#Sec12}

Overall, there were no significant relationships between MTHFR rs1801131 A/C and prostate cancer risk in any of the available genotype models. Moreover, to avoid publishing bias, two papers that were not consistent with HWE were excluded, so 9 case-control studies were left for analysis, and, to our regret, no association was also detected. Finally, based on ethnicity-stratified and source of control subgroup analysis, there remain no significant association were found (Table [2](#Tab2){ref-type="table"}).

### Bladder cancer {#Sec13}

Detailed results of the meta-analysis are shown in Table [2](#Tab2){ref-type="table"}. No statistically significant association was detected between MTHFR rs1801131 A/C and bladder cancer risk in the total group or in the all articles according to HWE. Interestingly, in the ethnicity subgroup analysis, there was a increased risk of bladder cancer in the Asian population (allelic contrast: OR = 1.35, 95% CI = 1.15--1.60, *P*~heterogeneity~ = 0.941, Fig. [5](#Fig5){ref-type="fig"}), and African population (heterozygote comparison: OR = 1.63, 95% CI = 1.17--2.25, *P*~heterogeneity~ = 0.498, Fig. [6](#Fig6){ref-type="fig"}), but not in Caucasians, or Mixed (Table [2](#Tab2){ref-type="table"}). Moreover, in the subgroup analysis in source of control, also increased relationship was detected in dominant genetic model (OR = 1.29, 95% CI = 1.09--1.54, *P*~heterogeneity~ = 0.235, Fig. [7](#Fig7){ref-type="fig"}). Fig. 5Forest plot of bladder cancer risk associated with the MTHFR rs1801131 polymorphism (C-allele vs. A-allele) by ethnicity subgroup. The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CIFig. 6Forest plot of bladder cancer risk associated with the MTHFR rs1801131 polymorphism (CA vs. AA) by ethnicity subgroup. The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CIFig. 7Forest plot of bladder cancer risk associated with the MTHFR rs1801131 polymorphism (CC + CA vs. AA) by source of control subgroup. The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI

### Renal cell carcinoma {#Sec14}

In the total and only HWE analysis, no increased relationship was found between MTHFR rs1801131 A/C and renal cell carcinoma (Table [2](#Tab2){ref-type="table"}).

Meta-regression {#Sec15}
---------------

Considering the subgroup of ethnicity, source of control, and control type as independent variables and the log (OR) as dependent variable, the random-effect meta-regression results were presented in Fig. [8](#Fig8){ref-type="fig"}. To estimate the functional relationship of the log OR with above three items, the analysis showed only a significant relationship for allele model (C-allele vs. A-allele) for the ethnicity with a regression coefficient of 0.009 in bladder cancer, rather than other subgroups and other urinary cancers, which means the heterogeneity for rs1801131 polymorphism in bladder cancer may be from the subgroup of ethnicity. Fig. 8Random-effect meta-regression of log odds ratio versus ethnicity (A1), source of control (A2), control type (A3), respectively in prostate cancer. Random-effect meta-regression of log odds ratio versus ethnicity (B1), source of control (B2), respectively in bladder cancer. Random-effect meta-regression of log odds ratio versus ethnicity (C1), source of control (C2), respectively in renal cell carcinoma

Publication bias diagnosis and sensitivity analysis {#Sec16}
---------------------------------------------------

Begg's funnel plot and Egger's test were performed to access the publication bias of the literature. The shape of the funnel plot did not reveal obvious asymmetry and the Egger's test suggested the absence of publication bias \[for example (CA vs. AA) (z = 1.61, *P* = 0.119 for Begg's test; t = 1.01, *P* = 0.314 for Egger's test, Figs. [9](#Fig9){ref-type="fig"}, [10](#Fig10){ref-type="fig"})\]. Instead of above, we also deleted each study involved in our meta-analysis to reflect the influence of the individual data-set on the pooled OR, then the corresponding pooled OR was not significantly altered, indicating that our results were statistically robust (for example: allelic contrast, Fig. [11](#Fig11){ref-type="fig"}). Fig. 9Begg's funnel plot for publication bias test (CA vs. AA). Each point represents a separate study for the indicated association. Log \[OR\], natural logarithm of OR. Horizontal line, mean effect sizeFig. 10Egger's publication bias plot (CA vs. AA). Each point represents a separate study for the indicated association. Horizontal line, mean effect sizeFig. 11Sensitivity analysis between the MTHFR rs1801131 polymorphism and whole urinary cancers' risk (C-allele vs. A-allele)

PolyPhen-2 analysis {#Sec17}
-------------------

To verify this association, we used the PolyPhen-2 tool to analyze the features of the rs1801131 mutant. A score of 0.021 was obtained from the analysis, suggesting the possibility of rs1801131 not being a damaging mutation (Fig. [12](#Fig12){ref-type="fig"}). Fig. 12Analysis of the effect of rs1801131 polymorphism on the MTHFR protein using the Polyphen-2 bioinformatics tool. The position of the black line represents the score, and a measure of how damaging the mutation could be as the protein function

Gene-gene interaction of online analysis {#Sec18}
----------------------------------------

String online server indicated that MTHFR gene interacts with numerous genes. The network of gene-gene interaction has been illustrated in Fig. [13](#Fig13){ref-type="fig"}. Fig. 13Human MTHFR interactions network with other genes obtained from String server. At least 10 genes have been indicated to correlate with MTHFR gene. MTR: 5-methylterahydrofolate-homocysteine methyltransferase; MTHFD: Methylenetetrahydrofolate dehydrogenase (NADP+ dependent); SHMT1: Serine hydroxymethyltransferase 1(soluble); TYMS: Thymidylate synthetase; SHMT2: Serine hydroxymethyltransferase 2 (mitochondrial); AMT: Aminomethyltransferase; MTHFD2L: MTHFD 2-like (347 aa); BHMT: Betaine-homocysteine S-methyltransferase; MTHFD1L: MTHFD 1-like

Discussion {#Sec19}
==========

Our study was focused on the MTHFR rs1801131 polymorphism. The mutant C-allele of the MTHFR rs1801131 polymorphism has been reported to reduce the MTHFR enzymatic activity of the wild type A-allele \[[@CR8]\], which may increase cancer risk. For example, Safarinejad et al. \[[@CR27]\] reported that reduced levels of MTHFR mRNA had an increased association with the risk in men bladder cancer, which may be explained by the hypothesis that reduced MTHFR mRNA level may influence the metabolism of folic acid, then decrease supply of 5-MTHF in serum, along with the increase other forms of folic acid, which leads to affect the synthesis of the pyrimidine and purine, resulting in damaged in DNA synthesis and repair, finally contributes to cancer development.

This is the first meta-analysis to estimate the relationship between MTHFR rs1801131 and urinary cancers' risk, involving approximately 9110 cancer cases and 12,105 controls. Increased associations were found between this polymorphism and urinary cancers. Moreover, in the specific bladder cancer, this polymorphism was associated with increased bladder cancer's susceptibility in Asians and Africans, but not Caucasians, in some different genetic models. The classic five genetic models were applied very popular and credible. If one of five model is significant, this group is considered as positive association. Additional, between different subgroups, such as ethnicity, it is normal that the associations were detected in different genetic models or the same models, because different items were existed among the groups. The polymorphism may act as a risk factor in urinary cancers, especially bladder cancer, possibly through the mechanism described above.

Interestingly, previous two meta-analysis reported that another MTHFR rs1801133 (C677T) had a decreased association in whole cancer risk and urinary cancers \[[@CR47], [@CR48]\]. Above two different polymorphisms in the same MTHFR gene had the complete opposite function. Following reasons may explain above results. First, different polymorphism sites may have the opposite effect on the expression of its host gene. Second, cancer is a complex disease, and may not be depended entirely on a gene or one kind of polymorphism, moreover, gene-gene or gene-environment factors may play a significant influence on the susceptibility of urinary cancers \[[@CR49]\].

In addition, we used the online analysis system-String to predict potential and functional partners (Fig. [12](#Fig12){ref-type="fig"}). Finally, 10 genes were predicted. The highest score of association was MTR (Score = 0.999), however, MTHFD1L was the last in line (Score = 0.896). Enzymes in one-carbon metabolism genes, such as MTR, MTHFD, TYMS, SHMT, MTHFR can both regulate the metabolism of folate, and low folate levels can induce carcinogenesis \[[@CR50]--[@CR53]\]. First, polymorphisms in MTR gene increase homocysteine in the plasma, resulting in changes to the folate pathway and increasing association of carcinogenesis \[[@CR54], [@CR55]\]. Second, MTHFD polymorphisms (G1958A and T401C) had a strong association with total plasma homocysteine levels and gastric cancer risk and were modulated by genotypes of MTHFR simultaneously \[[@CR56]\]. Third, the rs3819102 polymorphism in TYMS might increase susceptibility to the risk of lung cancer \[[@CR57]\]. Fourth, the SHMT1 C1420T polymorphism was associated with decreased risk of breast cancer \[[@CR58]\]. Above information predicted one-carbon metabolism genes: MTHFR and others may influence different kinds of tumors' development, which maybe become intervention and treatment target genes in the future.

There are some limitations inherent in the included studies. First, despite inclusion of all the eligible studies, the resultant sample size is still not large enough; this situation may increase the likelihood of type I and type II errors. Second, we just searched articles from Pubmed, some other studies maybe omitted. Third, the cancer may not be depended entirely on a gene or one kind of polymorphism, because different results were found in rs1801131 polymorphism, and in different SNPs (such as rs1801133 polymorphism) in the same MTHFR gene in current analysis, further studies should be to identified more valuable and credible polymorphisms. Fourth, it is necessary to evaluate the roles of some special environmental factors (such as age, gender, the body-mass index, diet, alcohol consumption, smoking status) and lifestyles. Fifth, significant associations were detected in different genetic models in the same subgroup, this inconsistency may indicate the influence of type I error by the repetitive comparison.

In summary, our present update analysis suggested novel evidence that the MTHFR rs1801131 polymorphism has a risk effect for urinary cancers, especially bladder cancer. Further studies with larger samples, are needed to evaluate associations between MTHFR rs1801131 polymorphism and urinary cancers' risk.

MTHFR

:   Methylenetetrahydrofolate reductase

5,10-MTHF

:   5,10-methylenetetrahydrofolate
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:   S-adenosylmethionine

ORs

:   Odds ratios

CIs

:   Confidence intervals
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:   Single nucleotide polymorphisms
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:   Hardy-Weinberg equilibrium
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